Proteolysis-targeting chimeras in drug development: A safety perspective.
Saved in:
| Title: | Proteolysis-targeting chimeras in drug development: A safety perspective. |
|---|---|
| Authors: | Moreau K; Oncology Safety, Clinical Pharmacology and Safety Sciences R&D, AstraZeneca, Cambridge, UK., Coen M; Oncology Safety, Clinical Pharmacology and Safety Sciences R&D, AstraZeneca, Cambridge, UK., Zhang AX; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts., Pachl F; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts., Castaldi MP; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Boston, Massachusetts., Dahl G; Structure, Biophysics and Fragment-Based Lead Generation, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Boyd H; Business Planning and Operations, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK., Scott C; Oncology Safety, Clinical Pharmacology and Safety Sciences R&D, AstraZeneca, Boston, Massachusetts., Newham P; Oncology Safety, Clinical Pharmacology and Safety Sciences R&D, AstraZeneca, Cambridge, UK. |
| Source: | British journal of pharmacology [Br J Pharmacol] 2020 Apr; Vol. 177 (8), pp. 1709-1718. Date of Electronic Publication: 2020 Feb 25. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Wiley Country of Publication: England NLM ID: 7502536 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5381 (Electronic) Linking ISSN: 00071188 NLM ISO Abbreviation: Br J Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
